Evidence map›Paper›PMID 41123579›Full record

ArticleeLife2025

Longitudinal assessment of DREADD expression and efficacy in the monkey brain.

Yuji Nagai, Yukiko Hori, Ken-Ichi Inoue, Toshiyuki Hirabayashi, Koki Mimura, Kei Oyama, Naohisa Miyakawa, Yuki Hori, Haruhiko Iwaoki, Katsushi Kumata and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in eLife, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Yuji NagaiAdvanced Neuroimaging Center, National Institutes for Quantum Science and Technology, Chiba, Japan.ORCID https://orcid.org/0000-0001-7005-0749
Yukiko HoriAdvanced Neuroimaging Center, National Institutes for Quantum Science and Technology, Chiba, Japan.ORCID https://orcid.org/0000-0003-1023-9587
Ken-Ichi InoueSystem Neuroscience Section, Center for the Evolutionary Origins of Human Behavior, Kyoto University, Inuyama, Japan.
Toshiyuki HirabayashiAdvanced Neuroimaging Center, National Institutes for Quantum Science and Technology, Chiba, Japan.
Koki MimuraAdvanced Neuroimaging Center, National Institutes for Quantum Science and Technology, Chiba, Japan.
Kei OyamaAdvanced Neuroimaging Center, National Institutes for Quantum Science and Technology, Chiba, Japan.
Naohisa MiyakawaAdvanced Neuroimaging Center, National Institutes for Quantum Science and Technology, Chiba, Japan.
Yuki HoriAdvanced Neuroimaging Center, National Institutes for Quantum Science and Technology, Chiba, Japan.
Haruhiko IwaokiAdvanced Neuroimaging Center, National Institutes for Quantum Science and Technology, Chiba, Japan.
Katsushi KumataDepartment of Advanced Nuclear Medicine Sciences, National Institutes for Quantum Science and Technology, Chiba, Japan.
Ming-Rong ZhangDepartment of Advanced Nuclear Medicine Sciences, National Institutes for Quantum Science and Technology, Chiba, Japan.
Masahiko TakadaAdvanced Neuroimaging Center, National Institutes for Quantum Science and Technology, Chiba, Japan.
Makoto HiguchiAdvanced Neuroimaging Center, National Institutes for Quantum Science and Technology, Chiba, Japan.
Takafumi MinamimotoAdvanced Neuroimaging Center, National Institutes for Quantum Science and Technology, Chiba, Japan.ORCID https://orcid.org/0000-0003-4305-0174

Funding

Japan Agency for Medical Research and Development JP23wm0625001Japan Agency for Medical Research and Development JP24wm0625307Japan Science and Technology Agency 10.52926/jpmjms2295Japan Science and Technology Agency 10.52926/jpmjpr22s3Japan Society for the Promotion of Science JP19K08138Japan Society for the Promotion of Science JP20H05955Japan Society for the Promotion of Science JP22H05157Japan Society for the Promotion of Science JP23K27098Japan Society for the Promotion of Science JP24H00069Japan Society for the Promotion of Science JP24H00734
6 · The paper itself

Abstract

Designer Receptors Exclusively Activated by Designer Drugs (DREADDs) offer a powerful means for reversible control of neuronal activity through systemic administration of inert actuators. Because chemogenetic control relies on DREADD expression levels, understanding and quantifying the temporal dynamics of their expression is crucial for planning long-term experiments in monkeys. In this study, we longitudinally quantified in vivo DREADD expression in macaque monkeys using positron emission tomography with the DREADD-selective tracer [

Indexed as

BrainDesigner DrugsAnimalsClozapineDependovirusLongitudinal StudiesMacaca mulattaMalePositron-Emission TomographyClozapineDesigner DrugsAAVDREADDsmonkeyneurosciencenonhuman primatesPETrhesus macaque

Identifiers

PMID41123579
PMCPMC12543322

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.